健帆生物：主营产品血液灌流器产品未被纳入国家及省级等集中带量采购范围

Core Viewpoint - The company reported its sales revenue from high-flow and low-flow dialysis devices and blood dialysis tubing through centralized procurement for the years 2024 and the first half of 2025, indicating a gradual increase in revenue contribution from these products [1] Group 1: Sales Revenue from Centralized Procurement - In 2024, the sales revenue from high-flow and low-flow dialysis devices through centralized procurement was 9.62 million yuan, accounting for 0.36% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in 2024 was 3.36 million yuan, representing 0.13% of the total revenue [1] - For the first half of 2025, the sales revenue from high-flow and low-flow dialysis devices through centralized procurement reached 15.2 million yuan, making up 1.34% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in the first half of 2025 was 2.45 million yuan, which accounted for 0.22% of the total revenue [1] Group 2: Product Inclusion in Centralized Procurement - As of now, the company's main product, blood perfusion devices, has not been included in the centralized procurement scope at the national or provincial levels [1]